New AAV supplement enhances gene therapy production

Ajinomoto CELLiST Korea, part of the Ajinomoto Group, has launched CELLiST™ AAV Production Supplement 1, a new culture medium additive designed to enhance viral vector productivity in gene therapy manufacturing.

Developed in collaboration with U.S.-based Forge Biologics, a leading CDMO for adeno-associated virus (AAV) development, the supplement has demonstrated a 1.3–2× increase in AAV production compared with standard culture methods. These results were highlighted at the Japan Society of Gene and Cell Therapy (JSGCT) in July 2025.

With the global gene therapy market expected to grow from US$7 billion in 2022 to US$46 billion by 2030, improving viral vector yields while reducing production costs is a critical challenge. CELLiST™ AAV Production Supplement 1 addresses this by combining Ajinomoto’s formulation expertise with Forge Biologics’ large-scale manufacturing know-how, supporting scalable, efficient, and reliable production.

Ajinomoto CELLiST Korea has over 30 years of experience in high-performance cell culture media, optimized for CHO and HEK293 cell lines. The company will use the new supplement to support customers across Asia seeking to boost viral vector output and streamline gene therapy manufacturing.

“We are excited to offer CELLiST™ AAV Production Supplement 1 to gene therapy developers,” said President Sugiyama of Ajinomoto CELLiST Korea. “Our aim is to help labs achieve higher productivity, better scalability, and more consistent results in their viral vector production.”

Ajinomoto CELLiST Korea continues to apply AminoScience-based innovations to accelerate biopharmaceutical manufacturing, from monoclonal antibodies to next-generation gene therapies.

More information online